You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Assessing the Data for Novel Nonalcoholic Steatohepatitis Therapies

  • Authors: Manal F. Abdelmalek, MD, MPH; Kathleen Corey, MD, MPH; Stephen A. Harrison, MD
  • CME / ABIM MOC Released: 3/17/2023
  • Valid for credit through: 3/17/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for gastroenterologists, hepatologists, diabetologists/endocrinologists, and primary care physicians.

The goal of this activity is for learners to be better able to diagnose and manage patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical evidence for emerging agents for the treatment of NAFLD/NASH
    • Mechanisms of action of investigational agents in late-stage development for NAFLD/NASH
    • Differences and similarities in clinical trial endpoints among experimental treatments for NAFLD/NASH


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Moderator

  • Manal F. Abdelmalek, MD, MPH

    Professor of Medicine 
    Mayo Clinic 
    Rochester, Minnesota 

    Disclosures

    Manal F. Abdelmalek, MD, MPH, has the following relevant financial relationships:
    Consultant or advisor for: Bristol Myers Squibb Company; Hanmi Pharm. Co., Ltd.; Inventiva; Madrigal Pharmaceuticals; NGM Biopharmaceuticals; Novo Nordisk; SonicIncytes; Theratechnologies Inc. (Canada)
    Research funding from: Allergan; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Durect Corporation; Enanta Pharmaceuticals, Inc.; ENYO Pharma; Galectin Therapeutics; Galmed Pharmaceuticals Ltd.; Genentech; GENFIT SA; Gilead Sciences, Inc.; Hanmi Pharm. Co., Ltd.; Intercept Pharmaceuticals, Inc.; Inventiva; Madrigal Pharmaceuticals; NGM Biopharmaceuticals; Novo Nordisk; Poxel SA; TARGET PharmaSolutions, Inc.; Viking Therapeutics

Faculty

  • Kathleen Corey, MD, MPH

    Associate Professor
    Harvard Medical School 
    Director, MGH Fatty Liver Clinic
    MGH Gastrointestinal Unit 
    Massachusetts General Hospital 
    Boston, Massachusetts 

    Disclosures

    Kathleen Corey, MD, MPH, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca
    Research funding from: Bristol Myers Squibb Company

  • Stephen A. Harrison, MD

    Medical Director
    Pinnacle Clinical Research
    San Antonio, Texas

    Disclosures

    Stephen A. Harrison, MD, has the following relevant financial relationships:
    Consultant or advisor for: AgomAb Therapeutics (former); Akero Therapeutics; Alentis (former); Alimentiv (former); Arrowhead Pharmaceuticals, Inc.; Axcella Health; Boston Pharma (former); B Riley FBR; BVF Partners (former); Chronwell Inc; CohBar Inc; Corcept Therapeutics Inc. (former); Echosens; ENYO Pharma; Foresite Labs; Galectin Therapeutics; Genfit Corp; Gilead Sciences, Inc.; Hepagene; Hepion Pharmaceuticals; HighTide Therapeutics; HistoIndex Pte Ltd.; Intercept Pharmaceuticals, Inc. (former); Ionis Pharmaceuticals; Kowa Research; Madrigal Pharmaceuticals; Medpace, Inc.; Metacrine; NGM Biopharmaceuticals; NorthSea Therapeutics B.V.; Novartis (former); Novo Nordisk; Nutrasource (former); PathAI Inc; Perspectum Diagnostics; Poxel SA; Prometic (former); Sagimet Biosciences; SonicIncytes; Terns Pharmaceuticals; Theratechnologies Inc. (Canada); Viking Therapeutics
    Research funding from: Akero Therapeutics; Axcella Health; Cirius Therapeutics; CiVi Biopharma, Inc.; Cymabay Therapeutics; ENYO Pharma; Galectin Therapeutics; Galmed Pharmaceuticals Ltd.; GENFIT SA; Gilead Sciences, Inc.; Hepion Pharmaceuticals; HighTide Therapeutics; Intercept Pharmaceuticals, Inc.; Madrigal Pharmaceuticals; Metacrine; NGM Biopharmaceuticals; NorthSea Therapeutics B.V.; Novartis Pharmaceuticals; Novo Nordisk; Poxel SA; Sagimet Biosciences; Viking Therapeutics
    Stock options from: Akero Therapeutics; Chronwell Inc; Cirius Therapeutics; Galectin Therapeutics; Genfit Corp; Hepion Pharmaceuticals; HistoIndex Pte Ltd.; Metacrine; NGM Biopharmaceuticals; NorthSea Therapeutics B.V.; SonicIncytes

Editor

  • Briana Betz, PhD

    Medical Education Director, Medscape, LLC 

    Disclosures

    Briana Betz, PhD, has no relevant financial relationships.  

Compliance Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Assessing the Data for Novel Nonalcoholic Steatohepatitis Therapies

Authors: Manal F. Abdelmalek, MD, MPH; Kathleen Corey, MD, MPH; Stephen A. Harrison, MDFaculty and Disclosures

CME / ABIM MOC Released: 3/17/2023

Valid for credit through: 3/17/2024, 11:59 PM EST

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print